首页> 外国专利> METHOD FOR ASSESSING RISK OF PROGRESSIVE COURSE OF OBLITERATING ARTERIAL SCLEROSIS OF LOWER EXTREMITIES

METHOD FOR ASSESSING RISK OF PROGRESSIVE COURSE OF OBLITERATING ARTERIAL SCLEROSIS OF LOWER EXTREMITIES

机译:评估下肢阻塞性动脉硬化进行性课程风险的方法

摘要

FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to surgery, and can be used for assessing of progressing obliterating arterial sclerosis of lower extremities risk in following 6 months. Method: monocyte index is taken into account, wherein the monocyte index less than 5 is estimated as 1 point, equal to or more than 5-0 points; taking into account atherogenicity index, the atherogenicity index less than 5 evaluated as 0 points, equal to or more than 5-2 points; considered total homo cystein, at level of total homo cystein less than 15 mcmol/l evaluated as 0 points, equal to 15 mcmol/l and less than or equal to 30 mcmol/l-1 point, more than 30 mcmol/l-2 points; other factors are allowed for progressing atherosclerosis, the use of statins in integrated treatment of atherosclerosis evaluated as 0 points, without receiving statins feature is evaluated as 2 points, all evaluated as 2 points, giving up of smoking for 11 months and more as 0 points. Then points are summed up, if amount of 6 points and more then high risk of atherosclerosis of lower extremities is probable.;EFFECT: invention provides integrated assessment of risk factors, enables assessing of obliterating arterial sclerosis of lower extremities risk in following 6 months, and if necessary to correct lipid-lowering and vasodilatatory therapy and timely assess necessity of surgical interventions.;1 cl, 5 tbl, 3 ex
机译:技术领域本发明涉及医学,即外科手术,并且可以用于评估在接下来的6个月中进展的下肢闭塞性动脉硬化风险。方法:考虑单核细胞指数,其中单核细胞指数小于5估计为1分,等于或大于5-0分;考虑到动脉粥样硬化指数,小于5的动脉粥样硬化指数为0分,等于或大于5-2分;被认为是总半胱氨酸,在总半胱氨酸水平低于15 mcmol / l时被评估为0分,等于15 mcmol / l并且小于或等于30 mcmol / l-1点,超过30 mcmol / l-2点其他因素允许进展为动脉粥样硬化,将他汀类药物用于动脉粥样硬化的综合治疗评估为0分,未接受他汀类药物的特征评估为2分,全部评估为2分,戒烟11个月以上为0分。然后将要点归纳起来,如果数量超过6分,那么下肢动脉粥样硬化的高风险是可能的。;效果:本发明提供了对危险因素的综合评估,可以评估在接下来的6个月内闭塞性下肢动脉硬化的风险,并在必要时纠正降脂和血管扩张疗法,并及时评估手术干预的必要性。1cl,5 tbl,3 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号